In 2025, Diddier Prada and a team from Mount Sinai analyzed 46 studies with over 100,000 participants worldwide, using a strict method to review links between prenatal acetaminophen use and neurodevelopmental issues like autism and ADHD. Acetaminophen is used by over 50% of pregnant women globally for pain or fever.

In 2013, Manfred Lamprecht and team from Graz, Austria, studied 34 obese women in a 12-week trial. They split them into four groups: one got a fruit/vegetable juice powder concentrate, another got the powder plus exercise, a third just exercised, and the last got a placebo. They measured inflammation, oxidative stress, and blood flow markers.

A 2025 cross-sectional observational study of nearly 350 women with premature ovarian insufficiency (POI) revealed that almost 30% experienced depressive symptoms, far higher than the general population—highlighting a hidden mental health crisis linked to early menopause.

A mouse study presented at ENDO 2025 by University of Michigan researchers found that tirzepatide (marketed as Mounjaro/Zepbound) caused ~20% weight loss in obese mice and dramatically slowed breast tumor growth, linking fat loss directly to improved cancer outcomes.

A 2021 review in Nutrients by Smith‑Ryan et al. highlights that women have 70–80% lower natural creatine stores than men, making supplementation especially impactful for their health and performance.